Idorsia Pharmaceuticals Ltd is an indirect, wholly-owned subsidiary of Idorsia Ltd. The Complainant, established in 2017 as a result of the demerger from Actelion, specializes in the discovery, development, and commercialization of innovative medicines. The Complainant has developed innovative drugs with the potential to transform the treatment paradigm in multiple therapeutic areas, including central nervous system, cardiovascular, and immunological disorders, as well as orphan diseases. Its portfolio includes products already on or close to the market – QUVIVIQ™ (daridorexant, indicated for the treatment of insomnia, including difficulties in falling asleep and\/or staying asleep) and TRYVIO™\/JERAYGO™ (aprocitentan, indicated for the treatment of hypertension, including resistant hypertension not adequately controlled by other antihypertensive medications) – as well as assets at various stages of clinical development. The Complainant employs approximately 500 individuals from around thirty nationalities and, according to the data available in its 2025 annual report, the Complainant reported a net revenue of CHF 214 million. <\/p>\n
The Complainant submits that the Disputed Domain Name constitutes an obvious misspelling of the Complainant’s IDORSIA mark, such misspelling being merely combined with the gTLD “.com”, which must be disregarded for comparison purposes. The Disputed Domain Name and the Complainant’s IDORSIA mark differ only in their initial letters, “I” and “L”, the latter being visually almost indistinguishable from the former when rendered in lowercase. Therefore, it is in the view of Complainant evident that this variation has been deliberately introduced to create confusion between them.<\/p>\n
The Complainant states that the Respondent has no rights or legitimate interests in respect of the Disputed Domain Name. The Respondent is neither connected to nor affiliated with the Complainant in any way and has not received any license, authorization, or consent to use the IDORSIA mark, or any typographical variation thereof, whether as part of the Domain Name or otherwise. In addition, the terms “Ldorsia” and “Ldorsia.com” do not appear to have any meaning in the English language.<\/p>\n
The Complainant notes that the Respondent has configured the Disputed Domain Name to include active MX (mail exchange) records. In the Complainant’s view, this technical configuration strongly indicates an intention on the part of the Respondent to exploit the Complainant’s IDORSIA mark for purposes such as e-mail phishing or other fraudulent schemes. This risk of abusive conduct is reinforced, in particular, by: (i) the fact that the Disputed Domain Name constitutes an evident misspelling of the Complainant’s IDORSIA mark and closely resembles its official domain name <idorsia.com>; and (ii) the fact that the only difference between the Disputed Domain Name and the Complainant’s IDORSIA mark lies in their initial letters, “I” and “L”, the latter being visually almost indistinguishable from the former when rendered in lowercase. As a result, Internet users receiving e-mails from addresses ending in “@ldorsia.com” are highly likely to assume that such communications originate from the Complainant and its domain name <idorsia.com>, which is clearly not the case.<\/p>", "other_legal_proceedings": "
The Panel is not aware of any other legal proceedings which are pending or decided and which relate to the Disputed Domain Name.<\/p>", "no_response_filed": "
The Complainant contends that the requirements of the Policy have been met and that the Disputed Domain Name should be transferred to it.<\/p>\n
No administratively compliant Response has been filed.<\/p>", "rights": "
The Complainant has, to the satisfaction of the Panel, shown the Disputed Domain Name is identical or confusingly similar to a trademark or service mark in which the Complainant has rights (within the meaning of paragraph 4(a)(i) of the Policy).<\/p>", "no_rights_or_legitimate_interests": "
The Complainant has, to the satisfaction of the Panel, shown the Respondent to have no rights or legitimate interests in respect of the Disputed Domain Name (within the meaning of paragraph 4(a)(ii) of the Policy).<\/p>", "bad_faith": "
The Complainant has, to the satisfaction of the Panel, shown the Disputed Domain Name has been registered and is being used in bad faith (within the meaning of paragraph 4(a)(iii) of the Policy).<\/p>", "procedural_factors": "
The Panel is satisfied that all procedural requirements under UDRP were met and there is no other reason why it would be inappropriate to provide a decision.<\/p>", "decision": "Accepted", "panelists": [ "Jan Schnedler" ], "date_of_panel_decision": "2026-06-16 00:00:00", "informal_english_translation": "
The Complainant holds a broad portfolio of trademark registrations worldwide for its medicines and commercial activities, including numerous registrations comprising or featuring the term IDORSIA:<\/p>\n
<\/p>\n